HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.
Autoantibody
Biomarker
HOMA2-B
Risk prediction
TrialNet Pathway to Prevention
Type 1 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
09
02
2021
accepted:
07
07
2021
pubmed:
14
10
2021
medline:
1
4
2022
entrez:
13
10
2021
Statut:
ppublish
Résumé
Methods to identify individuals at highest risk for type 1 diabetes are essential for the successful implementation of disease-modifying interventions. Simple metabolic measures are needed to help stratify autoantibody-positive (Aab+) individuals who are at risk of developing type 1 diabetes. HOMA2-B is a validated mathematical tool commonly used to estimate beta cell function in type 2 diabetes using fasting glucose and insulin. The utility of HOMA2-B in association with type 1 diabetes progression has not been tested. Baseline HOMA2-B values from single-Aab+ (n = 2652; mean age, 21.1 ± 14.0 years) and multiple-Aab+ (n = 3794; mean age, 14.5 ± 11.2 years) individuals enrolled in the TrialNet Pathway to Prevention study were compared. Cox proportional hazard models were used to determine associations between HOMA2-B tertiles and time to progression to type 1 diabetes, with adjustments for age, sex, HLA status and BMI z score. Receiver operating characteristic (ROC) analysis was used to test the association of HOMA2-B with type 1 diabetes development in 1, 2, 5 and 10 years. At study entry, HOMA2-B values were higher in single- compared with multiple-Aab+ Pathway to Prevention participants (91.1 ± 44.5 vs 83.9 ± 38.9; p < 0.001). Single- and multiple-Aab+ individuals in the lowest HOMA2-B tertile had a higher risk and faster rate of progression to type 1 diabetes. For progression to type 1 diabetes within 1 year, area under the ROC curve (AUC-ROC) was 0.685, 0.666 and 0.680 for all Aab+, single-Aab+ and multiple-Aab+ individuals, respectively. When correlation between HOMA2-B and type 1 diabetes risk was assessed in combination with additional factors known to influence type 1 diabetes progression (insulin sensitivity, age and HLA status), AUC-ROC was highest for the single-Aab+ group's risk of progression at 2 years (AUC-ROC 0.723 [95% CI 0.652, 0.794]). These data suggest that HOMA2-B may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in Aab+ individuals.
Identifiants
pubmed: 34642772
doi: 10.1007/s00125-021-05573-6
pii: 10.1007/s00125-021-05573-6
pmc: PMC8752172
mid: NIHMS1751299
doi:
Substances chimiques
Autoantibodies
0
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-100Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK085476
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085453
Pays : United States
Organisme : BLRD VA
ID : I01 BX001733
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103282
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061042
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085509
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK117009
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK093954
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127308
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK104166
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK119800
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061010
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK127786
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085466
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103153
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061058
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085499
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107013
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103266
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127236
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK127382
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK097512
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107014
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106994
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061034
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085461
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103180
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085465
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085504
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
JAMA. 2013 Jun 19;309(23):2473-9
pubmed: 23780460
Diabetes Care. 2012 Jun;35(6):1213-8
pubmed: 22446173
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S151-7
pubmed: 8529508
Ann N Y Acad Sci. 2008 Dec;1150:14-24
pubmed: 19120262
Diabetes. 2012 Jun;61(6):1331-7
pubmed: 22618768
JCI Insight. 2018 Aug 9;3(15):
pubmed: 30089716
Diabetologia. 2002 Dec;45(12):1658-66
pubmed: 12488955
Endokrynol Pol. 2014;65(3):176-80
pubmed: 24971917
Am J Transplant. 2018 Apr;18(4):990-997
pubmed: 29218834
Diabetes Care. 1999 May;22(5):818-22
pubmed: 10332688
Pediatr Diabetes. 2019 May;20(3):263-270
pubmed: 30628751
Pediatr Diabetes. 2009 Apr;10(2):97-104
pubmed: 18823409
Diabet Med. 1998 Apr;15(4):290-6
pubmed: 9585393
Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
pubmed: 24357209
Diabetes Care. 2015 Feb;38(2):271-6
pubmed: 25519451
Diabetes Care. 2015 Oct;38(10):1964-74
pubmed: 26404926
Diabetes Care. 1998 Dec;21(12):2191-2
pubmed: 9839117
N Engl J Med. 2019 Aug 15;381(7):603-613
pubmed: 31180194
Diabetes Care. 2007 Sep;30(9):2314-20
pubmed: 17536068
Diabetologia. 2004 Oct;47(10):1661-7
pubmed: 15480539
Diabetes. 1999 Sep;48(9):1779-86
pubmed: 10480608
Clin Chem. 1995 Aug;41(8 Pt 2):1248-55
pubmed: 7628115
Diabetes Res Clin Pract. 1998 Sep;41(3):191-6
pubmed: 9829348
Diabetologia. 2021 Apr;64(4):836-844
pubmed: 33496819
N Engl J Med. 2002 May 30;346(22):1685-91
pubmed: 12037147
Diabetes Care. 2008 Oct;31(10):1966-71
pubmed: 18628574
JAMA. 2020 Jan 28;323(4):339-351
pubmed: 31990315
Diabetes Care. 2011 Sep;34(9):1897-901
pubmed: 21750277
Diabetes Care. 2017 Nov;40(11):1494-1499
pubmed: 28860125
Pediatr Diabetes. 2011 Mar;12(2):85-90
pubmed: 20522170
Clin Chim Acta. 2011 Nov 20;412(23-24):2128-31
pubmed: 21843518
Diabetes Care. 2009 Sep;32(9):1603-7
pubmed: 19487644
Diabetes Care. 2020 Jan;43(1):5-12
pubmed: 31753960
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Diabetologia. 2019 Jan;62(1):24-27
pubmed: 30426167
Diabetologia. 2020 Mar;63(3):588-596
pubmed: 31768570
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Autoimmun. 2016 Jul;71:88-96
pubmed: 27068279